KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Shares Outstanding (Diluted Average): 2018-2025

Historic Shares Outstanding (Diluted Average) for Esperion Therapeutics (ESPR) over the last 7 years, with Sep 2025 value amounting to $200.7 million.

  • Esperion Therapeutics' Shares Outstanding (Diluted Average) rose 2.98% to $200.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $200.7 million, marking a year-over-year increase of 2.98%. This contributed to the annual value of $187.2 million for FY2024, which is 81.54% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Shares Outstanding (Diluted Average) of $200.7 million as of Q3 2025, which was up 1.61% from $197.5 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Shares Outstanding (Diluted Average) ranged from a high of $200.7 million in Q3 2025 and a low of $26.0 million during Q1 2021.
  • In the last 3 years, Esperion Therapeutics' Shares Outstanding (Diluted Average) had a median value of $188.8 million in 2024 and averaged $159.8 million.
  • Per our database at Business Quant, Esperion Therapeutics' Shares Outstanding (Diluted Average) fell by 9.41% in 2021 and then soared by 156.31% in 2022.
  • Over the past 5 years, Esperion Therapeutics' Shares Outstanding (Diluted Average) (Quarterly) stood at $28.9 million in 2021, then surged by 129.76% to $66.4 million in 2022, then soared by 55.26% to $103.1 million in 2023, then spiked by 81.54% to $187.2 million in 2024, then climbed by 2.98% to $200.7 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $200.7 million for Q3 2025, versus $197.5 million for Q2 2025 and $196.1 million for Q1 2025.